Promore Pharma’s Annual Report 2022

Regulatory

STOCKHOLM, 9 May, 2023 – The 2022 Annual report of Promore Pharma AB (publ) is now available on the Company’s website.

The annual report is available in PDF format on the Company’s website at:
https://www.promorepharma.com/en/section/investors/financial-reports/

Printed copies of the annual report can be ordered from Promore Pharma AB, Fogdevreten 2, SE-171 65 Solna, or by e-mail: shareholders@promorepharma.com

About Promore Pharma

Promore Pharma is a biopharmaceutical company that develops pharmaceutical product candidates for bioactive wound care. Today, the company has two drug candidates in late clinical development stages, that are based on endogenous peptides, and thus have a strong safety profile. These two products are intended for treatment of chronic wounds, and prevention of scarring on the skin and other tissues. The company is listed on the Nasdaq First North Growth Market.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com

Promore Pharmas Certified Adviser is Erik Penser Bank

Link to the report on our site

The full interim report is available at https://www.promorepharma.com/en/section/investors/financial-reports/

Attachments

Promore Pharma Annual Report 2022

Documents